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Major Depressive Disorder Preceding the Onset of   
Progressive Supranuclear Palsy 
 
 
 
Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by vertical 
supranuclear palsy and parkinsonian symptoms. The neuropsychiatric symptoms of PSP in-
clude anhedonia, depressed mood and cognitive impairment. Patients with PSP have an in-
creased risk for developing depressive disorders within the next year. However, it is rare to 
find that major depressive disorder was the antecedent diagnosis of a patient who was later 
diagnosed with PSP. We present here a patient who suffered from PSP with repetitive falls, a 
masked face and dysarthria after developing a major depressive disorder. 
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Introduction 
 
Progressive supranuclear palsy (PSP) is a neurodegenerative disease that causes ver-
tical supranuclear palsy and parkinsonian symptoms.
1,2 PSP is the second most common 
cause of Parkinsonism after Parkinson’s disease.
3 PSP also includes bulbar symptoms,
2,4
anhedonia, depressed mood,
5 dysexecutive dementia
6 etc. Depressed mood occurs in 
approximately 20% of PSP patients.
7 The patients who are diagnosed with PSP are more 
likely to develop depression within the next year.
8 However, there have been few re-
ports of cases with major depression as an antecedent symptom of PSP, which was dia-
gnosed later. 
We present here a patient with PSP who was hospitalized due to the presence of re-
current falling, masked face, and dysarthria, symptoms that became evident after devel-
opment of a major depressive disorder.   
 
Case 
 
A 51-year-old woman was admitted to the psychiatric department presenting with
neuroleptic-induced-Parkinsonism. She had no past history of psychiatric problems. 
Her depressed mood developed eight months prior to admission. Five months prior to 
the admission, she began to experience frequent falls. Eventually, her left hand’s 5
th fin-
ger was fractured due to a bad fall, and she was hospitalized at the orthopedic depart-
ment. Twenty days later, she was transferred to a local psychiatric clinic because her de-
pressed mood was aggravated. She was diagnosed with major depressive disorder with-
out psychotic features. 
Although the patient did not report being under stress, her admission notes indicat-
ed that her main symptoms included depression, anxious mood, loss of interests, in-
somnia, and suicidal ideation. Her short-term memory was slightly impaired. No other
cognitive examination was performed. The brain MRI obtained at the beginning of 
hospitalization showed no specific findings.  
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She was treated with 20 mg of escitalopram for depres-
sion and 37.5 mg of quetiapine for insomnia. Dysarthria 
and masked face then developed; nevertheless, she did not 
take any other medication because her level of subjective 
discomfort was not sufficiently severe. She was discharg-
ed twenty days after the hospitalization because her mood 
symptoms showed improvement.   
Fifty days before the next admission, her memory im-
pairment became progressively worse and she was disori-
ented as to time. No depressive mood was observed. The 
quetiapine was switched to 1.5 mg of risperidone. After 
switching medication, the masked face and her recurrent 
falls increased remarkably in intensity. 
She visited the emergency medical center because of a 
right orbital wall fracture that she sustained after falling 
forward. At that time, she manifested masked face, dysar-
thria and an unstable posture. The extrapyramidal symp-
toms were suspected to be caused by her small dose of an-
tipsychotics; therefore, she was admitted to the psychiatric 
department in order to differentiate her condition from de-
mentia with Lewy Bodies. 
On the mental status examination, she was alert, but 
disorientation as to time was observed. Her affect was 
blunted. There were no psychiatric symptoms such as hal-
lucination, delusion, depressed mood or suicidal ideation. 
The neurological examination showed pathological eye 
movements with voluntary saccades, vertical gaze palsy, 
bradykinesia, reduced arm swing, postural instability and 
a decreased rate of blinking. Ataxia, tremor and dyspha-
gia were not observed. No pathological findings were 
obtained from the standard laboratory tests, electrocardi-
ography (ECG), chest X-ray and electroencephalogram 
(EEG). The brain MRI revealed diffuse atrophy of the brain 
and the so-called penguin silhouette sign (atrophy of the 
midbrain tegmentum and pons, which resembles a lateral 
view of a standing penguin with a small head and a large 
body) on the midsagittal view. The size of the midbrain area 
was 55 mm
2, and the ratio of the midbrain tegmental area to 
the pons area was 0.12 on the midsagittal view (Figure 1). 
Upon examination by a neurologist, she was confirmed 
as suffering from PSP. She scored 17 points on the Mini-
mental status exam, 1 point on the clinical dementia rating, 
5 points on the Global Deterioration Scale, 4 points on the 
Geriatric Depression Scale, 15 points on the Barthel Index 
(the upper limit was 20) and 35 points on the Instrumen-
tal Activities of Living (the upper limit was 45). The neu-
ropsychological examination revealed working memory 
impairment, disorientation as to time and person, memory 
impairment and decline of frontal lobe executive function. 
Atypical antipsychotics and escitalopram were not used 
because the Parkinsonism was more severe than the psy-
chiatric and mood symptoms, except for the blunted affect. 
Six hundred mg of levodopa and 150 mg of decarboxylase 
inhibitor were used to treat the Parkinsonism. Although 
the Parkinsonism was not improved, she was transferred 
to the chronic geriatric hospital because of her poor eco-
nomic status. 
Two months after the discharge, we performed a follow-
up exam with permission from her family. Three hundred 
mg of levodopa, 75 mg of decarboxylase inhibitor and 10 
mg of selegiline were used to treat the Parkinsonism. Mask-
ed face and hypophonia were observed. She was not de-
pressed. The neurological examination showed vertical 
gaze palsy, voluntary saccades, a decreased blinking rate, 
stiff gait and bradykinesia. She had stopped falling down 
because of her improved postural stability. The mini-men-
tal status exam score was 21 points. Disorientation as to 
time, concentration impairment and dyscalculia had per-
sisted, while orientation to place and her memory recall 
were improved. 
 
Discussion 
 
The National Institute of Neurological Disorders and 
the Society for Progressive Supranuclear Palsy (NINDS-
SPSP)9 diagnostic criteria for “probable” PSP require that 
falls have occurred within the first year of symptom onset 
and that there is a vertical supranuclear eye movement dis-
order.  
Psychiatric symptoms for patients with PSP are com-
mon, yet the psychopathology of PSP is unclear because 
FIGURE 1. Magnetic resonance imaging. The midsagittal image 
shows marked atrophy of the midbrain tegmentum and the “pen-
guin silhouette” sign (arrow). The midbrain area was 65 mm
2 and the 
pons area was 550 mm
2. Therefore, the ratio of the midbrain area 
to the pons area was less than 0.12.  
 
 
 
 
MDD Preceding the Onset of PSP 
114 Psychiatry Invest 2009;6:112-114 
the psychiatric symptoms of PSP patients do not have spe-
cific features, and the patients with PSP are mainly treated 
by neurologists. 
The likelihood of developing depression increased with-
in the next year after diagnosis of PSP.
8 In this case, the pa-
tient’s depression developed three months before the onset 
of PSP with the symptom of recurrent falls. We could 
not define whether depression was a first symptom of PSP 
or if the depression was concurrent with PSP. Quante et 
al.
10 reported on one case for which depression preceded 
the onset of PSP. Because depression developed in the 
absence of a specific stressor, considering the report of 
Quante, we could assume that the depression of our pa-
tient was the first sign of PSP.   
Seventy-seven percent of PSP patients display apathy 
without depression.
11 Apathy is often misdiagnosed as de-
pression, which explains why antidepressants are ineffec-
tive. In this case, the depressive symptoms were improved 
by antidepressants, but the apathy persisted. 
In this case, making the proper differential diagnosis 
with the dementia of the Lewy Bodies was needed because 
of the patient’s Parkinsonism, repeated falls and severe 
neuroleptic sensitivity.
11,12 Yet the vertical gaze palsy and 
voluntary saccades were obvious. Further, the brain MRI 
demonstrated the penguin silhouette sign, which was de-
fined as marked atrophy of the midbrain tegmentum, 55 
mm
2 for the midbrain area, and a 0.12 ratio of the midbrain 
tegmentum area to the pons area on the midsagittal MRI. 
The midbrain area of <70 mm
2 (sensitivity=100%, spec-
ificity=91.3% for PSP) and the ratio of the midbrain teg-
mentum area to the pons area of <0.15 (sensitivity=100%, 
specificity=100% for PSP) strongly suggests a diagnosis 
of PSP.
11 Consequently, her symptoms of dementia were 
from the PSP.   
The reduced midbrain area and the ratio of the midbrain 
area to the area of the pons correlate with the duration of 
PSP. However, it is not clear when the findings of the brain 
MRI began. The study of Oba et al.
13 showed a midbrain 
area less than 70 mm
2 for a subject who was diagnosed 
with PSP 4 months previously. Hence, the specific find-
ings of PSP could appear in a patient for whom the onset 
was less than 1 year previously. There was a limitation in 
our case in that the brain MRI was not reviewed when the 
depression first developed. If the brain MRI could have 
been reviewed, then the onset of PSP would have become 
clearer. 
The treatment for PSP is to identify the target symptoms 
so that conservative management can be carried out. Levo-
dopa can be used to decrease the Parkinsonism, and forty 
to fifty percent of patients treated with Levodopa show 
modest improvement.
11 Antidepressants help to improve 
mood
2 and methlypenidate can reduce the apathy.
14 In this 
case, escitalopram improved the depressed mood, and com-
bined levodopa and carbidopa therapy reduced the fea-
tures of Parkinson disease. The cognitive functions were 
improved without treatment, which might have been tran-
sient, and so follow-up study was needed. The patient’s 
depression could recur because the antidepressant meds 
were stopped.   
We present here a patient who displayed depression as 
a first sign of PSP. Awareness of the possibly preceding 
psychiatric aspects like depression as the first symptom 
of developing PSP may help in the future to improved 
treatment. Further investigations should focus on the cau-
sality and the mechanism that underline the association 
between PSP and major depressive disorder. 
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